Panagora Asset Management Inc. Purchases 265,422 Shares of Cencora, Inc. $COR

Panagora Asset Management Inc. increased its stake in shares of Cencora, Inc. (NYSE:COR) by 13,962.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 267,323 shares of the company’s stock after buying an additional 265,422 shares during the period. Panagora Asset Management Inc. owned about 0.14% of Cencora worth $80,157,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the last quarter. Costello Asset Management INC bought a new stake in Cencora in the first quarter valued at approximately $28,000. Vermillion & White Wealth Management Group LLC boosted its position in Cencora by 69.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the period. Hantz Financial Services Inc. lifted its holdings in Cencora by 712.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after buying an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Cencora in the 2nd quarter worth about $61,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $368.93 on Monday. The firm has a market capitalization of $71.53 billion, a PE ratio of 37.96, a PEG ratio of 1.56 and a beta of 0.63. The stock’s fifty day moving average is $335.71 and its 200 day moving average is $307.83. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a $0.60 dividend. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Mizuho raised their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Robert W. Baird raised their target price on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group upped their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.09.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 46,640 shares of company stock worth $14,099,338. Insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.